Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioma 8Multiple Myeloma 7Sarcoma 6Rhabdoid Tumor 6Medulloblastoma 6Wilms Tumor 5Rhabdomyosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Lymphoma, Non-Hodgkin 5Lymphoma 5Histiocytosis, Langerhans-Cell 5Hepatoblastoma 5Ependymoma 5Central Nervous System Neoplasms 5Breast Neoplasms 5Prostatic Neoplasms 4Ovarian Neoplasms 4Osteosarcoma 4Pancreatic Neoplasms 3Lung Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Sarcoma, Ewing 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Malignant Solid Neoplasm 2

Interventions

luprolide acetate gel depot 1exemestane 1darolutamide 1X-Rays 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Granulosa cell tumor of the ovary × X-Rays × Clear all
NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡